Accelerate Diagnostics (AXDX) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Clean Environment LEED Life Cycle Lifecycle Materials Natural Resources Nature Offset Package Pandemic Raw Materials Wind Access African American Asian Benefits Black Charitable Community Culture Customer Death Demographic Disability Diversity Employee Ethnic Ethnicity Gender Health Care Healthcare Hiring Hispanic Latinx LGBTQ Reimbursement Retention Retirement Safety Satisfaction Skills Social Stakeholder Supplier Supply Chain Women Workforce Assessment Assurance Audit Board Oversight Bonus Classified Clawback Commitment Corporate Governance Corporate Purpose Ethics Executive Compensation Expert Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Investigation Lawsuit Leadership Litigation Long-term Majority Materiality Oversee Oversight Purpose R&D Reputation Research and Development Responsibility Responsible Shareholder Proposals Special Meeting Strategy Targets Tax Tenure Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 12, 2022, the Company held its 2022 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders:

(1)

elected 11 directors, each to hold office for a term to expire at the 2023 Annual Meeting of Shareholders and thereafter until their successors have been elected and qualified;

(2)

approved the Certificate of Amendment to increase the total number of authorized shares of the Company’s common stock by 100,000,000 shares, to a total of 200,000,000 shares;

(3)

approved the 2022 Plan;

(4)

approved, on an advisory basis, the compensation of the Company’s named executive officers; and

(5)

ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2022.

The voting results of each of these proposals, which are described in more detail in the Proxy Statement, are set forth below.

Proposal No. 1 – Election of Directors

Director Nominee
Thomas D. Brown	46,380,132	2,998,564	11,560,005
Wayne C. Burris	47,533,267	1,845,429	11,560,005
Louise L. Francesconi	47,389,907	1,988,789	11,560,005
Hany Massarany	47,107,233	2,271,463	11,560,005
Mark C. Miller	44,564,613	4,814,083	11,560,005
John Patience	47,210,760	2,167,936	11,560,005
Jack Phillips	47,535,672	1,843,024	11,560,005
Jack Schuler	46,117,612	3,261,084	11,560,005
Matthew W. Strobeck, Ph.D.	47,498,624	1,880,072	11,560,005
Frank J.M. ten Brink	47,531,574	1,847,122	11,560,005
Charles Watts, M.D.	46,066,960	3,311,736	11,560,005

Proposal No. 2 – Approval of Certificate Amendment

Votes For				Votes Against				Abstentions
	58,269,978				2,634,362				34,361

Proposal No. 3 – Approval of 2022 Plan

Votes For				Votes Against				Abstentions				Broker Non-Votes
	39,993,384				9,273,270				112,042				11,560,005

Proposal No. 4 – Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers

Votes For				Votes Against				Abstentions				Broker Non-Votes
	39,802,101				9,471,004				105,591				11,560,005

Proposal No. 5 – Ratification of Independent Registered Public Accounting Firm

Votes For				Votes Against				Abstentions
	59,651,454				1,254,724				32,523

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.